ClinicalTrials.gov

Trial records, trial locations and study sponsors

ClinicalTrials.gov helps users find studies and view public trial records, including sponsor-run or funded studies; site distances are approximate, and contacts, eligibility, or exact dates may be missing.

Get trial

Get the full public record for a clinical trial by NCT number or title. For ambiguous titles, returns the closest matching registered title. Dates without a recorded day are returned as null.

Your information

Trial

The trial title or NCT trial number, for example NCT04368728.

1 credit per run

Example results

Phase: Phase 3
Title: Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
Status: Completed
Sponsor: Cinnagen
Age Range: 18 Years and older
Start Date: 2021-12-15
Trial Link: clinicaltrials.gov
Trial Number: NCT05175625
Official Title: A Randomized, Two-Armed, Placebo-Controlled, Double-Blind, Parallel-Group Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen)
Results Posted: No
Completion Date: 2022-06-20
Purpose Summary: This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co. A total of 300 adult individuals received a single dose of either the SpikoGen vaccine or the saline placebo in a 5:1 ratio at 4 to 9 months after the second dose of a COVID-19 vaccine of any type. The injection was given in the deltoid muscle of the non-dominant arm. On day 14, the trial was unblinded, and the participants in the placebo group received a booster dose of the SpikoGen vaccine. For immunogenicity assessments, blood samples were collected on days 0 and 14 from all participants and on days 90 and 180 from those in the vaccine group only. For safety assessments, all participants were followed up for six months. Study hypotheses included: 1. A booster dose of the SpikoGen COVID-19 vaccine is safe and tolerable in adult subjects. 2. A booster dose of the SpikoGen COVID-19 vaccine induces strong immunogenicity against SARS-CoV-2 in adult subjects.
Eligibility Criteria: Inclusion Criteria: * Male or female ≥18 years * Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests * Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit * Subjects who have received two doses of a COVID-19 vaccine of any type between 4 to 9 months before the screening visit Exclusion Criteria: * Subjects with signs of active SARS-CoV-2 infection at the screening visit or within 72 hours prior to the screening visit * Subjects who have been diagnosed with a breakthrough infection after receiving two doses of a COVID-19 vaccine * Subjects with epilepsy or a history of febrile seizures * Subjects who receive immunosuppressive or cytotoxic medications. * Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. * Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. * Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study. * Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. * Female Subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection. * Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. * Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. * Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.
Number of Participants: 300
Arms: Arms
Name Type Treatments Description
SpikoGen COVID-19 Vaccine
Experimental
Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
—
Saline Placebo
Placebo Comparator
Biological: Saline placebo
—
Locations: Locations
City Country Facility Recruitment Status
Tehran
Iran
Orchid Life Department, Orchid Pharmed Company
—
Treatments: Treatments
Name Arms Type Description
SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
SpikoGen COVID-19 Vaccine
Biological
SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
Saline placebo
Saline Placebo
Biological
0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
Public Contacts: None
Primary Outcomes: Primary Outcomes
Measure Time Frame Description
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies
14 days after the booster dose
As measured by ELISA
Secondary Outcomes: Secondary Outcomes
Measure Time Frame Description
Incidence of solicited adverse events
For 7 days after the booster dose
Injection site pain, erythema, swelling, and induration, axillary swelling or tenderness ipsilateral to the side of injection, fever (oral temperature), headache, fatigue, myalgia, arthralgia, nausea, vomiting, and chills, as reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Incidence of unsolicited adverse events
For 14 days after the booster dose
As reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs)
For 6 months after the booster dose
As defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Geometric mean concentration (GMC) for S1 binding IgG antibodies
Days 0, 14, 90, and 180
As measured by ELISA
Geometric mean fold rise (GMFR) for S1 binding IgG antibodies
14 days after the booster dose
As measured by ELISA
Percentage of participants with seroconversion for S1 binding IgG antibodies
14 days after the booster dose
As measured by ELISA
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgG antibodies
14 days after the booster dose
As measured by ELISA
Geometric mean concentration (GMC) for receptor-binding domain (RBD) binding IgG antibodies
Days 0, 14, 90, and 180
As measured by ELISA
Geometric mean fold rise (GMFR) for receptor-binding domain (RBD) binding IgG antibodies
14 days after the booster dose
As measured by ELISA
Geometric mean concentration (GMC) for SARS-CoV-2 neutralizing antibodies
Days 0, 14, 90, and 180
As measured by ELISA
Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies
14 days after the booster dose
As measured by ELISA
Change in T-cell IFN-γ secretion from baseline to 14 days after the booster dose
Days 0 and 14
As measured by IGRA

Arms
Name	Type	Treatments	Description
SpikoGen COVID-19 Vaccine	Experimental	Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant	—
Saline Placebo	Placebo Comparator	Biological: Saline placebo	—

Locations
City	Country	Facility	Recruitment Status
Tehran	Iran	Orchid Life Department, Orchid Pharmed Company	—

Treatments
Name	Arms	Type	Description
SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant	SpikoGen COVID-19 Vaccine	Biological	SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
Saline placebo	Saline Placebo	Biological	0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm

Primary Outcomes
Measure	Time Frame	Description
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies	14 days after the booster dose	As measured by ELISA

Secondary Outcomes
Measure	Time Frame	Description
Incidence of solicited adverse events	For 7 days after the booster dose	Injection site pain, erythema, swelling, and induration, axillary swelling or tenderness ipsilateral to the side of injection, fever (oral temperature), headache, fatigue, myalgia, arthralgia, nausea, vomiting, and chills, as reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Incidence of unsolicited adverse events	For 14 days after the booster dose	As reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs)	For 6 months after the booster dose	As defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
Geometric mean concentration (GMC) for S1 binding IgG antibodies	Days 0, 14, 90, and 180	As measured by ELISA
Geometric mean fold rise (GMFR) for S1 binding IgG antibodies	14 days after the booster dose	As measured by ELISA
Percentage of participants with seroconversion for S1 binding IgG antibodies	14 days after the booster dose	As measured by ELISA
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgG antibodies	14 days after the booster dose	As measured by ELISA
Geometric mean concentration (GMC) for receptor-binding domain (RBD) binding IgG antibodies	Days 0, 14, 90, and 180	As measured by ELISA
Geometric mean fold rise (GMFR) for receptor-binding domain (RBD) binding IgG antibodies	14 days after the booster dose	As measured by ELISA
Geometric mean concentration (GMC) for SARS-CoV-2 neutralizing antibodies	Days 0, 14, 90, and 180	As measured by ELISA
Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies	14 days after the booster dose	As measured by ELISA
Change in T-cell IFN-γ secretion from baseline to 14 days after the booster dose	Days 0 and 14	As measured by IGRA

Example data · Run in Studio for fresh results.

About ClinicalTrials.gov

Search trials finds studies by condition or medicine, with optional location, distance, recruitment status, and phase filters.

Get trial returns a public study record using an NCT number or title, including treatments, arms, locations, and public contacts.

List company trials returns studies for a sponsor, with optional phase, status, and condition filters.

Built by Fous from clinicaltrials.gov and nominatim.openstreetmap.org and checked automatically; it last passed a check on Sep 29, 2026. Fous is not affiliated with ClinicalTrials.gov.

Actions

Get trial

1 credit per run

Get the full public record for a clinical trial by NCT number or title. For ambiguous titles, returns the closest matching registered title. Dates without a recorded day are returned as null.

What you provide

Field	Type	Required	Description
Trial`trial`	Text	Required	The trial title or NCT trial number, for example NCT04368728.Example: NCT05175625

What you get

Field	Type	Description
Arms`arms`	List
Name`arms[].name`	Text	Example: SpikoGen COVID-19 Vaccine
Type`arms[].type`	Text	Example: Experimental
Treatments`arms[].treatments`	List
Description`arms[].description`	Text
Phase`phase`	Text	Example: Phase 3
Title`title`	Text	Example: Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
Status`status`	Text	Example: Completed
Sponsor`sponsor`	Text	Example: Cinnagen
Age Range`age_range`	Text	Example: 18 Years and older
Locations`locations`	List
City`locations[].city`	Text	Example: Tehran
Country`locations[].country`	Text	Example: Iran
Facility`locations[].facility`	Text	Example: Orchid Life Department, Orchid Pharmed Company
Recruitment Status`locations[].recruitment_status`	Text
Start Date`start_date`	Date	Example: 2021-12-15
Treatments`treatments`	List
Arms`treatments[].arms`	List
Name`treatments[].name`	Text	Example: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Type`treatments[].type`	Text	Example: Biological
Description`treatments[].description`	Text	Example: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a…
Trial Link`trial_link`	Text	Example: https://clinicaltrials.gov/study/NCT05175625
Trial Number`trial_number`	Text	Example: NCT05175625
Official Title`official_title`	Text	Example: A Randomized, Two-Armed, Placebo-Controlled, Double-Blind, Parallel-Group…
Results Posted`results_posted`	Yes or no	Example: No
Completion Date`completion_date`	Date	Example: 2022-06-20
Public Contacts`public_contacts`	List
Name`public_contacts[].name`	Text
Role`public_contacts[].role`	Text
Email`public_contacts[].email`	Text
Phone`public_contacts[].phone`	Text
Facility`public_contacts[].facility`	Text
Purpose Summary`purpose_summary`	Text
Primary Outcomes`primary_outcomes`	List
Measure`primary_outcomes[].measure`	Text	Example: Percentage of participants with seroconversion for SARS-CoV-2 neutralizing…
Time Frame`primary_outcomes[].time_frame`	Text	Example: 14 days after the booster dose
Description`primary_outcomes[].description`	Text	Example: As measured by ELISA
Secondary Outcomes`secondary_outcomes`	List
Measure`secondary_outcomes[].measure`	Text	Example: Incidence of solicited adverse events
Time Frame`secondary_outcomes[].time_frame`	Text	Example: For 7 days after the booster dose
Description`secondary_outcomes[].description`	Text	Example: Injection site pain, erythema, swelling, and induration, axillary swelling or…
Eligibility Criteria`eligibility_criteria`	Text
Number of Participants`number_of_participants`	Number	Example: 300

Example result

For Trial: NCT05175625

JSON

{
  "arms": [
    {
      "name": "SpikoGen COVID-19 Vaccine",
      "type": "Experimental",
      "treatments": [
        "Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant"
      ],
      "description": null
    }
  ],
  "phase": "Phase 3",
  "title": "Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine",
  "status": "Completed",
  "sponsor": "Cinnagen",
  "age_range": "18 Years and older",
  "locations": [
    {
      "city": "Tehran",
      "country": "Iran",
      "facility": "Orchid Life Department, Orchid Pharmed Company",
      "recruitment_status": null
    }
  ],
  "start_date": "2021-12-15",
  "treatments": [
    {
      "arms": [
        "SpikoGen COVID-19 Vaccine"
      ],
      "name": "SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant",
      "type": "Biological",
      "description": "SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm"
    }
  ],
  "trial_link": "https://clinicaltrials.gov/study/NCT05175625",
  "trial_number": "NCT05175625",
  "official_title": "A Randomized, Two-Armed, Placebo-Controlled, Double-Blind, Parallel-Group Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19…",
  "results_posted": false,
  "completion_date": "2022-06-20",
  "public_contacts": [],
  "purpose_summary": "This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subu…",
  "primary_outcomes": [
    {
      "measure": "Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies",
      "time_frame": "14 days after the booster dose",
      "description": "As measured by ELISA"
    }
  ],
  "secondary_outcomes": [
    {
      "measure": "Incidence of solicited adverse events
…

List company trials

1 credit per run

List studies run or funded by a sponsor, newest start date first. Dates without a full day are returned as null.

What you provide

Field	Type	Required	Description
Phase`phase`	Text	Optional	Study phase to include, such as phase_3; any includes all phases.Example: Phase 3
Status`status`	Text	Optional	Study recruitment status, such as recruiting; any includes all statuses.Example: Recruiting
Sponsor`sponsor`	Text	Required	Company or organization sponsoring or collaborating on studies, such as Pfizer.Example: Pfizer
Condition`condition`	Text	Optional	Condition to match, such as obesity.Example: Obesity
Max Results`max_results`	Number	Optional	Maximum number of studies to return, such as 50 (up to 200).Example: 10

What you get

Field	Type	Description
Trials`trials`	List	Matching trials sorted by start date, newest first.
Phase`trials[].phase`	Text	Study phase or phases in words.Example: Phase 3
Status`trials[].status`	Text	Overall study status in words.Example: Recruiting
Conditions`trials[].conditions`	List	Conditions studied.
Start Date`trials[].start_date`	Text	Start date as YYYY-MM-DD when the day is known.Example: 2026-06-10
Trial Link`trials[].trial_link`	Text	ClinicalTrials.gov study page.Example: https://clinicaltrials.gov/study/NCT07595549
Trial Title`trials[].trial_title`	Text	Public study title.Example: A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in…
Trial Number`trials[].trial_number`	Text	NCT study number.Example: NCT07595549
Number of Participants`trials[].number_of_participants`	Number	Enrolled or planned number of participants.Example: 954
Primary Completion Date`trials[].primary_completion_date`	Text	Primary completion date as YYYY-MM-DD when the day is known.Example: 2028-05-04

Example result

For Phase: Phase 3, Status: Recruiting, Sponsor: Pfizer, Condition: Obesity, Max Results: 10

JSON

{
  "trials": [
    {
      "phase": "Phase 3",
      "status": "Recruiting",
      "conditions": [
        "Obesity",
        "Overweight and/or Obesity",
        "Overweight"
      ],
      "start_date": "2026-06-10",
      "trial_link": "https://clinicaltrials.gov/study/NCT07595549",
      "trial_title": "A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity",
      "trial_number": "NCT07595549",
      "number_of_participants": 954,
      "primary_completion_date": "2028-05-04"
    }
  ]
}

Search trials

1 credit per run

Find ClinicalTrials.gov studies for a condition or medicine, with optional location, distance, recruitment status, and phase filters. With a location, results are ordered by distance to their closest eligible registered site. Site distances are approximate straight-line miles; contact and eligibility information may be missing.

Uses ClinicalTrials.gov and nominatim.openstreetmap.org.

What you provide

Field	Type	Required	Description
Phase`phase`	Text	Optional	Study phase, for example phase_3 or any.Example: Phase 3
Location`location`	Text	Optional	City, state, or country for nearby trials, for example Boston, MA.Example: Boston, MA
Condition`condition`	Text	Required	Condition or medicine to search, for example breast cancer or semaglutide.Example: Semaglutide
Max Results`max_results`	Number	Optional	Maximum number of trials to return, for example 20 (up to 100).Example: 3
Distance (miles)`distance_miles`	Number	Optional	Search radius in miles when a location is given, for example 50.Example: 50
Recruiting Only`recruiting_only`	Yes or no	Optional	Include only studies recruiting or preparing to recruit, for example true.Example: Yes

What you get

Field	Type	Description
Trials`trials`	List
Sex`trials[].sex`	Text	Example: All
Phase`trials[].phase`	Text	Example: Not applicable
Status`trials[].status`	Text	Example: Recruiting
Sponsor`trials[].sponsor`	Text	Example: University College Dublin
Age Range`trials[].age_range`	Text	Example: 18 Years and older
Conditions`trials[].conditions`	List
Start Date`trials[].start_date`	Text	Example: 2022-06-22
Trial Link`trials[].trial_link`	Text	Example: https://clinicaltrials.gov/study/NCT04174755
Trial Title`trials[].trial_title`	Text	Example: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
Contact Name`trials[].contact_name`	Text	Example: Aoife Cotter, PhD
Trial Number`trials[].trial_number`	Text	Example: NCT04174755
Contact Email`trials[].contact_email`	Text	Example: [email protected]
Contact Phone`trials[].contact_phone`	Text	Example: 562-826-8000
Distance (miles)`trials[].distance_miles`	Number	Example: 0.1
Nearest Site City`trials[].nearest_site_city`	Text	Example: Dublin
Healthy Volunteers`trials[].healthy_volunteers`	Yes or no	Example: No
Nearest Site State`trials[].nearest_site_state`	Text	Example: Dublin
Nearest Site Country`trials[].nearest_site_country`	Text	Example: Ireland
Nearest Site Facility`trials[].nearest_site_facility`	Text	Example: Mater Misericordiae University Hospital

Example result

For Condition: Semaglutide, Max Results: 3

JSON

{
  "trials": [
    {
      "sex": "All",
      "phase": "Not applicable",
      "status": "Recruiting",
      "sponsor": "University College Dublin",
      "age_range": "18 Years and older",
      "conditions": [
        "Obesity",
        "HIV-1-infection"
      ],
      "start_date": "2022-06-22",
      "trial_link": "https://clinicaltrials.gov/study/NCT04174755",
      "trial_title": "Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV",
      "contact_name": "Aoife Cotter, PhD",
      "trial_number": "NCT04174755",
      "contact_email": "[email protected]",
      "contact_phone": null,
      "distance_miles": null,
      "nearest_site_city": "Dublin",
      "healthy_volunteers": false,
      "nearest_site_state": "Dublin",
      "nearest_site_country": "Ireland",
      "nearest_site_facility": "Mater Misericordiae University Hospital"
    },
    {
      "sex": "All",
      "phase": "Phase 3",
      "status": "Recruiting",
      "sponsor": "VA Office of Research and Development",
      "age_range": "18 Years to 80 Years",
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "start_date": "2026-07-28",
      "trial_link": "https://clinicaltrials.gov/study/NCT07218354",
      "trial_title": "Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)",
      "contact_name": "Larry Albers, MD",
      "trial_number": "NCT07218354",
      "contact_email": "[email protected]",
      "contact_phone": "562-826-8000",
      "distance_miles": null,
      "nearest_site_city": "Long Beach",
      "healthy_volunteers": true,
      "nearest_site_state": "California",
      "nearest_site_country": "United States",
      "nearest_site_facility": "VA Long Beach Healthcare System, Long Beach, CA"
    }
  ]
}

For developers

Run this workflow from your own code. In Studio, turn on Developer mode and create an API key.

cURL

# First set your key: export FOUS_API_KEY='YOUR_FOUS_API_KEY'
: "${FOUS_API_KEY:?Set FOUS_API_KEY before running this example}"

curl 'https://api.fous.com/v1/query' \
  --fail-with-body --silent --show-error --max-time 120 \
  -H "Authorization: Bearer $FOUS_API_KEY" \
  -H 'Content-Type: application/json' \
  --data-raw '{
  "api": "@clinicaltrials-gov",
  "visibility": "public",
  "operation": "get_trial",
  "version": 1,
  "input": {
    "trial": "NCT05175625"
  },
  "response": {
    "format": "json"
  }
}'

What you can do with it

Find recruiting trials for a condition near a city
Review a trial’s treatments, arms, locations, and public contacts
Compare company studies by phase, status, or condition
Track study start dates and participant counts by sponsor

Questions

Is Fous affiliated with ClinicalTrials.gov?

No. Fous is not affiliated with ClinicalTrials.gov. This workflow reads the public clinicaltrials.gov website and returns its data.

How much does it cost?

Each run costs 1 credit. With pay-as-you-go, a credit costs 1¢; monthly plans cost less per credit.

Do I need a ClinicalTrials.gov account?

No. You only need a Fous account.

How current is the data?

Fous gets the data from clinicaltrials.gov when you run it; repeating the same request within a day may return the saved result. Fous checks this workflow automatically; it last passed a check on Sep 29, 2026.